Align Technology heads into its July 29 earnings report with short interest climbing steadily and options traders more cautious than usual — a setup worth watching as the stock sits 19% below the Street's average target.
Short interest has been the defining story of the past month. Bears have rebuilt positions aggressively, with SI % of free float rising to 7.0%, up more than 26% over the past 30 days. The acceleration has been steady rather than spiky — shares short climbed from roughly 4.0 million in late May to just over 5.0 million by June 30, the highest level in the trailing window. Despite this build, the borrow market remains wide open. Availability runs near 1,355% — meaning there are roughly 13 shares available to borrow for every one already lent out — and cost to borrow has actually fallen 23% on the week to 0.45%. That combination tells you this is a deliberate positioning move, not a borrow-driven squeeze setup.
Options are leaning defensive without being extreme. The put/call ratio is running at 1.29, modestly above its 20-day average of 1.22, but the z-score of 0.93 keeps it well within normal territory. The PCR has traded in a noticeably tighter band since mid-June, holding above 1.25 most days — a shift from the 1.08–1.16 range that prevailed through early June. That quiet persistence of put-heavy positioning reinforces the cautious tone from the short book without suggesting outright panic.
The Street remains constructive, but most of the recent analyst action is two months old and should be read as backdrop rather than current catalyst. As of late April, the analyst consensus had been moving in one direction — upward. Several firms raised targets after Q1 results, including Evercore ISI lifting to $220, Piper Sandler to $235, and a fresh Citigroup initiation at $240 with a Buy. Morgan Stanley, the lone equal-weight holdout among the named movers, also nudged its target higher to $188. The mean target across the group is $209, implying roughly 24% upside from the current $168.66 — a gap that reflects genuine Street optimism, but also the reality that the stock has drifted lower since those calls were made. The bull case centres on Invisalign's market leadership and a 3–4% revenue growth outlook for 2026. The bear case is more specific: ASP for clear aligners has been under pressure for seven consecutive quarters as volume shifts toward lower-cost markets, and Q1 operating margin guidance disappointed.
Earnings history adds a useful data point without resolving the debate. The most recent print, on May 20, produced a 5% one-day rally. Before that, the April 29 Q1 report landed flat to slightly negative — down 0.7% on the day and off 1.9% over the following week. The pattern is inconsistent, which means neither the bears nor the bulls can lean hard on prior reactions as a guide.
The ORTEX short score has crept up to 48.4 this week, its highest reading in the past 10 sessions, reflecting the steady SI build. That is a middling absolute reading — not a crowded-short signal — but the direction of travel into a known catalyst is the detail worth tracking into July 29.
See the live data behind this article on ORTEX.
Open ALGN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
